Strategic Investment Opportunity to engage CureCMT and other specialty disease investors to support expansion of ReviR's precision medicine platform for Charcot-Marie-Tooth and related neurogenetic targets, highlighting collaboration potential and co-development funding avenues.

RNA Modulator Demand Position ReviR as a source for novel small molecule RNA modulators addressing neurogenetic diseases, appealing to biotech partners seeking first-in-class RNA-targeted therapies and potential licensing or co-development agreements.

AI-Driven Platform Emphasize the AI-based platform that expands beyond traditional protein targets, offering access to previously undruggable disease targets; pitch to pharma/biotech firms aiming to accelerate target discovery and de-risk early-stage programs.

Grant & Milestone Access Leverage recent CIRM funding and disease-focused grants to showcase a track record of non-dilutive financing and milestone-driven development, suggesting partnership opportunities tied to funded milestones and accelerated programs.

Strategic Partnerships Highlight previous collaborations (Kennedy's Disease Association, SBMA programs) as evidence of patient-centric, disease-specific alliances; approach patient advocacy groups and rare disease consortia for co-development, access programs, and rapid-pipeline expansion.